Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans

María Eugenia Goya, Feng Xue, Cristina Sampedro-Torres-Quevedo, Sofia Arnaouteli, Lourdes Riquelme-Dominguez, Andrés Romanowski, Jack Brydon, Kathryn L. Ball, Nicola R. Stanley-Wall, Maria Doitsidou*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

How the gut microbiome affects Parkinson's disease remains unclear. Goya et al. show that the probiotic B. subtilis strain PXN21 inhibits and clears α-synuclein aggregation in a C. elegans model. The bacterium acts via metabolites and biofilm formation to activate protective pathways in the host, including DAF-16/FOXO and sphingolipid metabolism.

Original languageEnglish
Pages (from-to)367-380.e7
JournalCell Reports
Volume30
Issue number2
DOIs
Publication statusPublished - 14 Jan 2020
Externally publishedYes

Keywords

  • B. subtilis
  • biofilm
  • C. elegans
  • DAF-16/FOXO
  • dietary restriction
  • microbiota
  • Parkinson's disease
  • probiotics
  • sphingolipid metabolism
  • α-synuclein

Fingerprint

Dive into the research topics of 'Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans'. Together they form a unique fingerprint.

Cite this